David Foehr Sells 862 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 862 shares of CeriBell stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $18.80, for a total transaction of $16,205.60. Following the completion of the transaction, the vice president directly owned 37,751 shares in the company, valued at $709,718.80. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Thursday, May 21st, David Foehr sold 987 shares of CeriBell stock. The stock was sold at an average price of $18.00, for a total transaction of $17,766.00.
• On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The stock was sold at an average price of $17.80, for a total transaction of $81,168.00.

CeriBell Trading Down 0.5%

NASDAQ:CBLL opened at $18.70 on Thursday. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $24.33. The firm has a fifty day simple moving average of $19.08 and a 200-day simple moving average of $19.29. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $709.48 million, a P/E ratio of -11.47 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. On average, equities research analysts anticipate that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

Several hedge funds have recently added to or reduced their stakes in CBLL. Strs Ohio purchased a new stake in CeriBell in the first quarter valued at $27,000. Caitong International Asset Management Co. Ltd boosted its holdings in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell in the third quarter valued at $33,000. CWM LLC boosted its holdings in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. BTIG Research reiterated a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. Finally, Canaccord Genuity Group lowered their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.